SCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections

The data from these three presentations provide a deeper understanding of ibrexafungerps activity against a broad spectrum of fungal infections caused by Candida species, including azole- and echinocandin-resistant strains.